Diet Initiation Baseline
Placeholder: starting point before gluten elimination begins.
- >10x ULN: tTG-IgA baseline (Placeholder metric)
- High: Symptom score (Placeholder metric)
- Marsh 3: Villous atrophy (Placeholder metric)
- 0 mo: Diet duration (Placeholder metric)
Baseline serology and symptoms
Placeholder short paragraph describing pre-diet antibody and symptom state.
Strict Adherence — 3-Month Mark
Placeholder: early response window under strict adherence.
- -30%: tTG-IgA change (Placeholder metric)
- Partial: Symptom relief (Placeholder metric)
- >95%: Adherence needed (Placeholder metric)
- 3 mo: Follow-up (Placeholder metric)
Early adherence response
Placeholder short paragraph on the three-month adherence checkpoint.
tTG Antibody Decline
Placeholder: sustained decline in tTG titers over months.
- ~4-6 mo: Half-life estimate (Placeholder metric)
- <20 U/mL: Normal range (Placeholder metric)
- High impact: Strictness effect (Placeholder metric)
- 6-12 mo: Typical timeline (Placeholder metric)
Titer decay dynamics
Placeholder short paragraph describing the antibody decay curve.
Symptom Resolution
Placeholder: symptoms fade as mucosal healing progresses.
- Weeks: GI symptom relief (Placeholder metric)
- 1-2 yrs: Mucosal healing (Placeholder metric)
- Months: Fatigue resolution (Placeholder metric)
- Improved: Quality of life (Placeholder metric)
Symptom-antibody relationship
Placeholder short paragraph on symptom lag behind serology.
Accidental Exposure Setback Risk
Placeholder: cross-contamination causes temporary antibody spikes.
- +20-40%: Exposure spike (Placeholder metric)
- Weeks: Recovery time (Placeholder metric)
- Cross-contact: Common sources (Placeholder metric)
- Elevated: Risk with low strictness (Placeholder metric)
Managing accidental exposure
Placeholder short paragraph on setback risk and recovery.
Placeholder: strict adherence lowers both spike size and recovery time.